The Enclomiphene regulatory status in India has come under scrutiny after the country’s drug regulator flagged the manufacture and marketing of enclomiphene-containing products and their combinations without the required central regulatory approval. State and Union Territory drug regulators have been directed to identify entities involved and take appropriate enforcement action.
The development is important for pharmacy professionals, pharmaceutical companies, drug inspectors, pharmacists and healthcare-sector stakeholders because it highlights the regulatory requirements applicable to unapproved drug products.
Quick Summary
Enclomiphene is currently under regulatory scrutiny in India after the DCGI flagged the manufacture and marketing of enclomiphene-containing products and combinations without the required central approval. State and UT drug regulators have been asked to identify manufacturers, marketers, distributors and retailers involved and initiate appropriate regulatory action.
Enclomiphene Regulatory Update 2026 – Overview
According to reports on the DCGI communication, the regulator has raised concerns about products containing enclomiphene and its combinations being manufactured and/or marketed without the requisite permission from the Central Licensing Authority.
The direction has been sent to State and Union Territory drug regulators for identification of entities involved in the supply chain and appropriate enforcement action.
Key Details
| Particular | Details |
|---|---|
| Drug | Enclomiphene |
| Drug Class | Selective Estrogen Receptor Modulator (SERM) |
| Reported Therapeutic Use | Associated with stimulation of natural testosterone and sperm production |
| Regulatory Issue | Manufacture/marketing without required central approval |
| Regulator | DCGI/CDSCO |
| Action Directed To | State and UT Drugs Controllers |
| Entities to Identify | Manufacturers, marketers, distributors and retailers |
| Regulatory Action | Appropriate/strict enforcement action |
| Action-Taken Report | Sought from states/UTs |
| Latest Reported Update | August 2026 |
The reported regulatory action concerns the approval and marketing status of products in India, rather than simply the pharmacological classification of enclomiphene.
What Is Enclomiphene?
Enclomiphene is a selective estrogen receptor modulator (SERM). It has been investigated for its potential to stimulate the body’s endogenous production of testosterone and sperm.
The current Indian regulatory concern, however, relates to the manufacture and marketing of enclomiphene-containing products without the required regulatory approval.
Therefore, it is important to distinguish between:
- The pharmacological action of a drug.
- Its regulatory approval status in a particular country.
- The authorization required to manufacture and market a medicinal product.
Why Has DCGI Flagged Enclomiphene?
The DCGI has reportedly flagged instances where drug products containing enclomiphene and its combinations were being manufactured and/or marketed without the required permission from the Central Licensing Authority.
CDSCO’s New Drugs division is responsible for processing applications for new-drug approvals and related regulatory matters.
The latest direction therefore focuses on identifying products and entities that may be operating without the necessary central approval.
What Action Has DCGI Directed States to Take?
State and UT Drugs Controllers have been directed to identify entities involved in the manufacture and supply of the products.
The reported categories include:
- Manufacturers
- Marketers
- Distributors
- Retailers
Authorities have been asked to take appropriate regulatory/enforcement action against entities found dealing with unapproved enclomiphene-containing products.
Regulatory Action May Include
The exact action in an individual case would depend on the findings of the concerned regulator and applicable law.
The reported direction specifically calls for enforcement against entities found involved in the manufacture or marketing of the unapproved products.
Action-Taken Report Sought From States
The regulatory exercise also includes submission of an Action-Taken Report (ATR).
Such a report can help the central authorities understand:
- Which companies or entities were identified.
- What regulatory violations were found.
- What action was initiated.
- What steps were taken to stop further marketing of the products.
The latest reporting indicates that states have been asked to provide details of the action taken.
Enclomiphene Approval Status in India
Is Enclomiphene Approved for Manufacture and Marketing in India?
According to the DCGI communication reported in August 2026, enclomiphene and its combinations have not received the required approval from the Central Licensing Authority for manufacture and marketing in India.
This is the central issue behind the latest regulatory action.
Important Clarification
The regulatory update should not be interpreted as a general statement that every form of enclomiphene-related activity is prohibited under every circumstance.
The reported action specifically concerns the manufacture and marketing of drug products without the required approval. Regulatory requirements can vary depending on the nature and purpose of the activity.
Why Is Regulatory Approval Important?
Drug regulation is intended to ensure that medicinal products placed on the market meet applicable requirements relating to quality, safety and efficacy.
CDSCO’s regulatory framework includes processes for reviewing applications for new drugs and drug products before they are approved for marketing in India.
The manufacture, sale and distribution of drugs in India are regulated under the Drugs and Cosmetics Act, 1940 and associated rules, through licensing and regulatory oversight.
The enclomiphene development therefore highlights why manufacturers and other supply-chain participants must verify the appropriate regulatory permissions before marketing a medicinal product.
What Should Manufacturers and Sellers Know?
Companies and other entities involved in pharmaceutical products should verify the regulatory status of the products they manufacture, market, distribute or sell.
For products containing enclomiphene, businesses should particularly ensure that:
- The relevant regulatory approvals are in place.
- Manufacturing permissions are valid.
- Marketing claims comply with applicable requirements.
- Distribution and sale are conducted under valid licences.
- The product’s regulatory status is verified with the competent authority where necessary.
Entities should rely on the latest official regulatory communication rather than promotional or unofficial claims about approval status.
Why Is This Update Important for Pharmacy Professionals?
The Enclomiphene regulatory update 2026 is relevant for pharmacy students and professionals because it provides an example of how drug regulatory authorities respond to the circulation of products that may not have the required approval.
For B.Pharm, M.Pharm, Pharm.D, D.Pharm, pharmacist and Drug Inspector aspirants, the topic can also be useful for understanding:
- CDSCO and DCGI functions
- New-drug approval
- Drug licensing
- Unapproved medicines
- Regulatory enforcement
- State drug-control administration
- Pharmaceutical compliance
This update may also be relevant for pharmacovigilance and pharmaceutical regulatory affairs discussions.
Enclomiphene Regulatory Update – Key Highlights
| Topic | Key Information |
|---|---|
| Drug | Enclomiphene |
| Class | SERM |
| Regulatory Concern | Unapproved manufacture and marketing |
| Authority | DCGI/CDSCO |
| States Directed | State/UT Drugs Controllers |
| Entities Under Scrutiny | Manufacturers, marketers, distributors and retailers |
| Combinations | Enclomiphene-containing combinations also flagged |
| Required Action | Identify entities and initiate appropriate enforcement |
| ATR | Action-Taken Report sought |
| Reported Date | August 2026 |
Enclomiphene vs Regulatory Approval: Important Difference
It is useful to understand the distinction between drug action and regulatory approval.
| Aspect | Meaning |
|---|---|
| Pharmacology | How a drug acts in the body |
| Therapeutic indication | Medical use for which a product may be intended |
| Regulatory approval | Permission granted by the competent authority under the applicable framework |
| Manufacturing authorization | Permission required for lawful manufacture |
| Marketing authorization | Approval required for lawful marketing, where applicable |
A drug’s pharmacological properties do not by themselves establish that a particular product is approved for manufacture and marketing in India.
Important Points for Pharmacy Students
For competitive examinations such as GPAT, Drug Inspector and pharmacist recruitment exams, remember the following:
- DCGI = Drugs Controller General of India.
- CDSCO = Central Drugs Standard Control Organization.
- CDSCO is India’s central drug regulatory organization.
- New-drug applications are reviewed through the applicable regulatory framework.
- Manufacturing and marketing of medicines require compliance with applicable regulatory requirements.
- The 2026 enclomiphene issue concerns unapproved manufacture and marketing according to the reported DCGI communication.
FAQs on Enclomiphene Regulatory Status in India
1. Is enclomiphene approved in India?
According to the DCGI communication reported in August 2026, enclomiphene and its combinations do not have the required central approval for manufacture and marketing in India.
2. Why has DCGI flagged enclomiphene?
The DCGI flagged the reported manufacture and marketing of enclomiphene-containing products and combinations without the required central regulatory approval.
3. Who has been asked to take action?
State and Union Territory Drugs Controllers have been directed to identify entities involved in the manufacture, marketing, distribution and sale of the products and take appropriate regulatory action.
4. What type of drug is enclomiphene?
Enclomiphene is classified as a selective estrogen receptor modulator (SERM).
5. What is the reported use of enclomiphene?
The regulatory report describes enclomiphene as being indicated to stimulate the body’s natural production of testosterone and sperm.
6. What is an Action-Taken Report (ATR)?
An Action-Taken Report (ATR) records the regulatory steps taken by the concerned authorities following a direction or enforcement exercise.
7. Is this update important for pharmacy students?
Yes. It is relevant to pharmacy students because it illustrates important concepts related to CDSCO, DCGI, drug approval, licensing and regulatory enforcement.
8. Where can I check official drug regulatory information?
The Central Drugs Standard Control Organization (CDSCO) is the appropriate government regulatory source for information on drug approvals, regulatory notices and related matters.
Conclusion
The latest Enclomiphene regulatory update in India highlights the importance of regulatory approval before the manufacture and marketing of medicinal products. The DCGI has reportedly directed State and UT drug regulators to identify manufacturers, marketers, distributors and retailers dealing with unapproved enclomiphene-containing products and combinations and to take appropriate enforcement action.
For pharmacy professionals and students, the development is an important example of drug regulation, CDSCO oversight, new-drug approval and regulatory enforcement in India.
Manufacturers and sellers dealing with enclomiphene-containing products should verify the applicable regulatory permissions and comply with the requirements of the competent authorities.
Recommended Products
